Skip to main content
Intended for healthcare professionals

Abstract

Liposarcoma (LPS) typically occurs in the extremities and retroperitoneum, but rarely occurs in visceral organs such as pancreas. Only few cases of primary pancreatic LPS have been reported in literature. Here we describe the first case of primary pancreatic LPS in a patient receiving continuous ambulatory peritoneal dialysis (CAPD). This patient was a 60-year-old female who had been on CAPD for 3 years due to kidney failure from type 2 diabetes mellitus. She presented with a 2-week history of intermittent fever measuring up to 38 degrees Celsius. The septic workup including peripheral blood, peritoneal dialysis (PD) fluid, urine, and sputum cultures were all negative. Intravenous piperacillin/tazobactam was empirically started but there was persistent fever with increasing blood leukocytosis (blood white cell count up to 37.5×109/L). In addition, she developed cloudy peritoneal dialysate, suggestive of PD peritonitis, 2 weeks into the hospitalization. Piperacillin/tazobactam was then switched to intravenous meropenem and intraperitoneal vancomycin. Computerized tomography scan of the abdomen showed a large heterogeneous enhancing mass with central hypoattenuating area arising from the pancreatic tail. There were also local invasion and multiple metastatic lesions. Ultrasound-guided fine-needle biopsy of the abdominal mass confirmed the diagnosis of primary dedifferentiated LPS of the pancreas. In view of the advanced nature of the disease, she was treated with palliative chemotherapy. Her clinical condition deteriorated progressively and she passed away from pneumonia 10 months after the diagnosis of LPS. Our case shows that patients on CAPD with pancreatic LPS can develop symptoms mimicking infectious peritonitis and also highlights the importance of considering malignancies in the differential diagnosis of fever and unexplained leukocytosis after ruling out infective causes.

Get full access to this article

View all access and purchase options for this article.

References

1. Zhao Y, Hu S, Sun H, et al. Pancreatic liposarcoma: a case report. Oncol Lett 2025; 29: 268.
2. Thway K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: an updated review. Semin Diagn Pathol 2019; 36: 112–121.
3. Zhang H, Yu S, Wang W, et al. Primary mesenchymal tumors of the pancreas in a single center over 15 years. Oncol Lett 2016; 12: 4027–4034.
4. Wilson N, Issak A, Amin K, et al. Primary pancreatic liposarcoma: an unexpected cause of a pancreatic mass. ACG Case Rep J 2023; 10: e01242.
5. Henricks WH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21: 271–281.
6. Abukhiran IA, Jasser J, Syrbu S. Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours. J Clin Pathol 2020; 73: 310–313.
7. Yarih GD, Bryan HW, Antonio OJJ, et al. Paraneoplastic Leukemoid reaction in soft tissue sarcoma: a case report and literature review. Int J Surg Case Rep 2024; 120: 109819.
8. Sakamoto A, Matono H, Yoshida T, et al. Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSF-producing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage. World J Surg Oncol 2007; 5: 131.
9. Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92: 2399–2405.
10. Akimoto T, Muto S, Kutsuwada T, et al. Peritoneal dialysis and malignancy: an experience with a patient complicated by gastric carcinoma. Clin Med Insights Case Rep 2019; 12: 1179547619835176.
11. Trinh E, Manera K, Scholes-Robertson N, et al. The burden of home dialysis: an overlooked challenge. Clin J Am Soc Nephrol 2024; 19: 1191–1197.
12. Karam S, Rosner MH, Sprangers B, et al. Cancer therapy in patients with reduced kidney function. Nephrol Dial Transplant 2024; 39: 1976–1984.
13. Labaki C, Rawadi E, Chebel R, et al. Anti-neoplastic agents for patients on peritoneal dialysis: a systematic review. Crit Rev Oncol Hematol 2020; 150: 102947.